Compare SEVN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SEVN | SGMT |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 169.4M |
| IPO Year | 2008 | 2021 |
| Metric | SEVN | SGMT |
|---|---|---|
| Price | $7.57 | $10.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $10.50 | ★ $26.13 |
| AVG Volume (30 Days) | 120.6K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | $2,000,000.00 |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $39.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.37 | $4.50 |
| 52 Week High | $11.15 | $11.24 |
| Indicator | SEVN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 65.22 |
| Support Level | $7.41 | $6.60 |
| Resistance Level | $7.84 | $11.15 |
| Average True Range (ATR) | 0.12 | 0.51 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 26.37 | 70.54 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.